- ESR1 : Development and validation of improved hiPSC cardiomyocyte assays to study cardiac safety. Ncardia.
- ESR2 : Development and validation of cardiomyocyte model as a predictive assay to assess functional and structural cardiac liabilities. UCB Biopharma.
- ESR3 : Empowering the predictivity and speed of hiPSC cardiomyocyte assays by utilising a machine learning approach. NOTOCORD.
- ESR4 : Development of novel telemetry implants with added 3D micro-GPS functionality. TSE systems.
- ESR5 : Extending NOTOCORD-SenseTM with behavioural analysers in a cloud-based architecture. NOTOCORD.
- ESR6 : Development of a methodology and software to analyse and quantify social interactions and behaviour. Weizmann Institute.
- ESR7 : Validation and use of novel telemetry implants with added 3D micro-GPS functionality. Boehringer Ingelheim.
- ESR8 : An in silico approach to monitor and predict haemodynamics during safety pharmacology studies. Inria Research Centre.
- ESR9 : Development of mass spectrometry imaging (MSI) tools to study drug distribution and associated tissue-specific effects. Maastricht University.
- ESR10 : Measuring arterial stiffness at different scales: a new toolbox for safety pharmacology? Univeristy of Antwerp.
- ESR11 : New preclinical screen in safety pharmaoclogy assessment: detection of cardiovascular effects in “failed” NCE. University of Nottingham.
- ESR12 : Assessing the cardiovascular safety liabilities of growth factor inhibition. University of Nottingham.
- ESR13 : Optimize risk analysis and preventive measures to mitigate cardiovascular adverse effects. Univeristy of Antwerp.
- ESR14 : Chemotherapy-induced functional myocardial alterations: is a heart failure with preserved ejection fraction (HFpEF) stage preceding HFrEF? Univeristy of Antwerp.
- ESR15 : Personalized safety pharmacology against drug-evoked proarrhythmia. Maastricht University.